Sensitivity_NN of_IN Three_NP Urinary_NP Antigen_NP Tests_NP Associated_NP with_IN Clinical_NP Severity_NP in_IN a_DT Large_JJ Outbreak_NN of_IN Legionnaires_NP '_POS Disease_NN in_IN The_DT Netherlands_NP In_IN 1999_CD an_DT outbreak_NN involving_VBG 188_CD patients_NNS with_IN Legionnaires_NP '_POS disease_NN (_( LD_NP )_) occurred_VBD among_IN visitors_NNS to_TO a_DT flower_NN show_NN in_IN the_DT Netherlands_NPS ._SENT Two_CD enzyme_NN immunoassays_NNS (_( Binax_NP and_CC Biotest_NP )_) and_CC one_CD immunochromatographic_JJ assay_NN (_( Binax_NP NOW_NP )_) were_VBD tested_VBN ,_, using_VBG urine_NN samples_NNS from_IN LD_JJ patients_NNS from_IN the_DT 1999_CD outbreak_NN ._SENT Sensitivity_NN was_VBD calculated_VBN using_VBG positive_JJ culture_NN and/or_CC seroconversion_NN as_IN the_DT "_`` gold_JJ standard_NN "_'' in_IN outbreak-related_JJ patients_NNS with_IN radiographically_RB confirmed_VBN pneumonia_NN who_WP fulfilled_VBD the_DT epidemiological_JJ critera_NN ._SENT The_DT Binax_NP EIA_NP ,_, Biotest_NP EIA_NP ,_, and_CC Binax_NP NOW_NP assay_NN showed_VBD overall_JJ sensitivities_NNS of_IN 69_CD ,_, 71_CD ,_, and_CC 72_CD %_NN ,_, respectively_RB ._SENT When_WRB the_DT tests_NNS were_VBD performed_VBN with_IN concentrated_JJ urine_NN samples_NNS ,_, the_DT overall_JJ sensitivities_NNS increased_VBD to_TO 79_CD ,_, 74_CD ,_, and_CC 81_CD %_NN ,_, respectively_RB ._SENT Using_VBG multiple_JJ logistic_JJ regression_NN analysis_NN with_IN backward_JJ elimination_NN ,_, a_DT statistically_RB significant_JJ association_NN was_VBD found_VBN between_IN clinical_JJ severity_NN and_CC test_NN sensitivity_NN for_IN all_DT tests_NNS ._SENT For_IN patients_NNS with_IN mild_JJ LD_NN ,_, the_DT test_NN sensitivities_NNS ranged_VBD from_IN 40_CD to_TO 53_CD %_NN ,_, whereas_IN for_IN patients_NNS with_IN severe_JJ LD_NN who_WP needed_VBD immediate_JJ special_JJ medical_JJ care_NN ,_, the_DT sensitivities_NNS reached_VBD 88_CD to_TO 100_CD %_NN ._SENT These_DT findings_NNS have_VBP major_JJ implications_NNS for_IN the_DT diagnostic_JJ process_NN in_IN patients_NNS with_IN mild_JJ pneumonia_NN and_CC suggest_VBP that_IN patients_NNS with_IN mild_JJ pneumonia_NN may_MD go_VB underdiagnosed_JJ if_IN urine_NN antigen_NN tests_NNS alone_RB are_VBP used_VBN ._SENT Legionnaires_NNS '_POS disease_NN (_( LD_NP )_) is_VBZ an_DT acute_JJ pneumonia_NN caused_VBN by_IN Legionella_NP ,_, a_DT rod-shaped_JJ gram-negative_JJ bacillus_NN ubiquitous_JJ in_IN (_( man-made_JJ )_) aquatic_JJ reservoirs_NNS ._SENT Currently_RB 43_CD Legionella_NP species_NNS and_CC 65_CD serogroups_NNS have_VBP been_VBN described_VBN ._SENT In_IN the_DT United_NP States_NPS ,_, over_IN 90_CD %_NN of_IN Legionnaires_NP '_POS disease_NN cases_NNS are_VBP caused_VBN by_IN Legionella_NP pneumophila_NP ,_, of_IN which_WDT 70_CD %_NN of_IN strains_NNS belong_VBP to_TO serogroup_VB type_NN 1_CD ._SENT Legionella_NP spp._NP are_VBP responsible_JJ for_IN 1_CD to_TO 5_CD %_NN of_IN cases_NNS of_IN community-acquired_JJ pneumonia_NN (_( CAP_NP )_) ._SENT Clinically_RB and_CC radiographically_RB ,_, LD_NP cannot_MD be_VB distinguished_VBN from_IN pneumonias_NNS caused_VBN by_IN other_JJ microbial_JJ pathogens_NNS ._SENT Because_IN of_IN the_DT high_JJ mortality_NN rate_NN in_IN patients_NNS with_IN LD_JJ requiring_VBG hospitalization_NN ,_, early_JJ diagnosis_NN to_TO enable_VB adequate_JJ antimicrobial_JJ treatment_NN is_VBZ potentially_RB life-saving_JJ ._SENT Diagnosis_NN of_IN LD_NN in_IN patients_NNS with_IN symptomatic_JJ pneumonia_NN is_VBZ based_VBN on_IN culture_NN ,_, serologic_JJ testing_NN ,_, or_CC antigen_NN detection_NN in_IN urine_NN ._SENT Isolation_NN of_IN Legionella_NP from_IN respiratory_JJ secretions_NNS is_VBZ not_RB a_DT very_RB sensitive_JJ diagnostic_JJ test_NN (_( 25_CD to_TO 75_CD %_NN sensitivity_NN )_) and_CC has_VBZ the_DT disadvantage_NN of_IN delay_NN ,_, because_IN a_DT positive_JJ result_NN is_VBZ not_RB available_JJ until_IN at_IN least_JJS 3_CD days_NNS of_IN incubation_NN ._SENT Seroconversion_NP is_VBZ a_DT diagnostic_JJ test_NN with_IN a_DT high_JJ sensitivity_NN and_CC a_DT high_JJ (_( serogroup-dependant_JJ )_) specificity_NN ,_, but_CC it_PP is_VBZ of_IN limited_JJ clinical_JJ value_NN since_IN it_PP may_MD take_VB up_RP to_TO 9_CD weeks_NNS for_IN patients_NNS to_TO develop_VB detectable_JJ antibodies_NNS ._SENT In_IN contrast_NN to_TO the_DT other_JJ tests_NNS mentioned_VBN above_IN ,_, urinary_JJ antigen_NN tests_NNS combine_VBP reasonable_JJ sensitivity_NN and_CC high_JJ specificity_NN with_IN rapid_JJ results_NNS ._SENT The_DT reported_VBN sensitivities_NNS of_IN both_DT enzyme_NN immunoassay_NN (_( EIA_NP )_) and_CC immunochromatographic_JJ test_NN (_( ICT_NP )_) show_VBP great_JJ variation_NN :_: 50_CD to_TO 90_CD %_NN ._SENT These_DT variations_NNS may_MD be_VB explained_VBN by_IN differences_NNS in_IN patient_JJ characteristics_NNS ,_, the_DT serogroup_NN with_IN which_WDT the_DT patient_NN is_VBZ infected_VBN ,_, the_DT timing_NN of_IN collection_NN the_DT urine_NN sample_NN in_IN the_DT course_NN of_IN illness_NN ,_, and_CC whether_IN the_DT urine_NN is_VBZ concentrated_VBN before_IN testing_NN ._SENT To_TO assess_VB the_DT value_NN of_IN the_DT urinary_JJ antigen_NN tests_NNS in_IN a_DT large_JJ outbreak_NN situation_NN ,_, we_PP used_VBD three_CD widely_RB used_VBN and_CC commercially_RB available_JJ tests_NNS with_IN urine_NN specimens_NNS from_IN patients_NNS with_IN outbreak-related_JJ LD_NN :_: the_DT Biotest_NP EIA_NP ,_, the_DT Binax_NP EIA_NP ,_, and_CC the_DT Binax_NP NOW_NP test_NN ._SENT Patients_NNS ._SENT |_SYM In_IN February_NP 1999_CD an_DT outbreak_NN involving_VBG 188_CD cases_NNS of_IN LD_NP occurred_VBD in_IN Bovenkarspel_NP ,_, The_DT Netherlands_NPS ._SENT The_DT outbreak_NN investigation_NN indicated_VBD that_IN a_DT whirlpool_NN displayed_VBN at_IN the_DT consumer_NN product_NN division_NN of_IN an_DT annual_JJ flower_NN show_NN was_VBD the_DT most_RBS likely_JJ source_NN of_IN infection_NN ._SENT Genotyping_NP revealed_VBD that_IN isolates_NNS from_IN 27_CD patients_NNS were_VBD identical_JJ to_TO one_CD of_IN the_DT environmental_JJ L._NP pneumophila_NN serogroup_NN 1_CD strains_NNS ._SENT All_DT 180_CD hospitalized_VBN patients_NNS with_IN a_DT confirmed_VBN Legionella_NP pneumonia_NN were_VBD included_VBN in_IN this_DT study_NN after_IN written_JJ consent_NN was_VBD obtained_VBN from_IN patients_NNS or_CC their_PP$ relatives_NNS ._SENT A_DT confirmed_VBN case_NN of_IN LD_NP (_( "_`` gold_JJ standard_NN "_'' )_) was_VBD defined_VBN as_IN a_DT patient_NN who_WP fulfilled_VBD the_DT epidemiological_JJ criteria_NNS (_( visitor_NN to_TO the_DT 1999_CD Bovenkarspel_NP flowershow_NN or_CC member_NN of_IN the_DT exhibition_NN staff_NN )_) and_CC who_WP suffered_VBD from_IN symptoms_NNS compatible_JJ with_IN pneumonia_NN ,_, who_WP showed_VBD radiological_JJ signs_NNS of_IN infiltration_NN ,_, and_CC who_WP showed_VBD laboratory_NN evidence_NN of_IN infection_NN with_IN L._NP pneumophila_NP ._SENT Laboratory_NP evidence_NN included_VBD (_( i_NP )_) isolation_NN of_IN L._NP pneumophila_NP from_IN a_DT respiratory_JJ sample_NN cultured_VBN on_IN buffered_VBN charcoal_NN yeast_NN extract_NN supplemented_VBN with_IN alpha-ketoglutarate_NNS followed_VBN by_IN genotyping_NN and_CC subsequent_JJ comparison_NN to_TO the_DT environmental_JJ strains_NNS of_IN the_DT Bovenkarspel_NP outbreak_NN ;_: or_CC (_( ii_NNS )_) a_DT fourfold_JJ rise_NN in_IN the_DT titer_NN of_IN immunoglobulin_NN M_NP (_( IgM_NP )_) antibodies_NNS to_TO L._NP pneumophila_NN in_IN paired_VBN acute-phase_NN and_CC convalescent-phase_NN sera_NN ,_, with_IN final_JJ titers_NNS of_IN >=1:32_NN in_IN accord_NN with_IN the_DT 99_CD %_NN cutoff_NN values_NNS found_VBN in_IN a_DT serosurvey_NN of_IN healthy_JJ volunteers_NNS representative_JJ of_IN the_DT Dutch_JJ population_NN using_VBG a_DT microagglutination_NN IgM_NP ,_, serotype_NN 1_CD ,_, antibody_NN assay_NN ;_: or_CC (_( iii_NN )_) seroconversion_NN to_TO positive_JJ IgM_NP or_CC IgG_NP antibodies_NNS to_TO L._NP pneumophila_NN in_IN paired_VBN acute-phase_NN and_CC convalescent-phase_NN sera_NN ,_, with_IN age-specific_JJ titers_NNS in_IN accord_NN with_IN the_DT 99_CD %_NN cutoff_NN values_NNS found_VBN in_IN a_DT serosurvey_NN among_IN healthy_JJ volunteers_NNS representative_JJ of_IN the_DT Dutch_JJ population_NN ,_, using_VBG a_DT commercial_JJ enzyme-linked_JJ immunosorbent_JJ assay_NN to_TO detect_VB IgM_NP and_CC IgG_NP serotype_NN 1_CD to_TO 7_CD antibodies_NNS (_( Serion_NP ELISA_NP ;_: Institut_NP Virion\Serion_NP GmbH_NP ,_, Wurzburg_NP ,_, Germany_NP )_) ._SENT For_IN isolation_NN and_CC genotyping_NN of_IN L._NP pneumophila_NP from_IN sputum_NN samples_NNS ,_, the_DT National_NP Institute_NP for_IN Public_NP Health_NP and_CC the_DT Environment_NP was_VBD the_DT reference_NN laboratory_NN ;_: for_IN detection_NN of_IN antibodies_NNS against_IN L._NP pneumophila_NP in_IN serum_NN ,_, the_DT Regional_NP Laboratory_NP of_IN Public_NP Health_NP Tilburg_NP was_VBD the_DT reference_NN laboratory_NN ._SENT Classification_NN of_IN severity_NN of_IN disease_NN ._SENT |_SYM To_TO investigate_VB the_DT relation_NN between_IN test_NN sensitivity_NN and_CC severity_NN of_IN disease_NN ,_, the_DT patients_NNS were_VBD divided_VBN into_IN three_CD clinical_JJ categories_NNS for_IN CAP_NP ._SENT Clinical_JJ data_NNS were_VBD collected_VBN from_IN the_DT hospital_NN chart_NN by_IN using_VBG a_DT standardized_JJ case_NN record_NN form_NN ._SENT Severity_NN of_IN pneumonia_NN was_VBD scored_VBN according_VBG to_TO the_DT minor_JJ criteria_NNS for_IN severity_NN of_IN CAP_NP advised_VBD by_IN the_DT American_NP Thoracic_NP Society_NP ,_, using_VBG the_DT following_VBG clinical_JJ criteria_NNS at_IN hospital_NN admission_NN :_: (_( i_NP )_) respiratory_JJ frequency_NN above_IN 30_CD breaths_NNS per_IN minute_NN ,_, (_( ii_NP )_) PaO2_NP below_IN 60_CD mm_NN Hg_NP or_CC O2_NP saturation_NN below_IN 92_CD %_NN ,_, (_( iii_NNS )_) bilateral_JJ or_CC multilobar_JJ infiltration_NN on_IN chest_NN X-ray_NN ,_, and_CC (_( iv_NN )_) systolic_JJ blood_NN pressure_NN below_IN 90_CD mm_NN Hg_NN or_CC diastolic_JJ blood_NN pressure_NN below_IN 60_CD mm_NN Hg_NP ._SENT Patients_NNS with_IN a_DT radiographically_RB proven_VBN unilateral_JJ unilobar_NN pneumonia_NN ,_, but_CC without_IN signs_NNS or_CC symptoms_NNS according_VBG to_TO the_DT above-mentioned_JJ criteria_NNS ,_, were_VBD classified_VBN as_IN CAP_NP category_NN 1_CD (_( mild_JJ pneumonia_NN )_) ._SENT CAP_NN category_NN 2_CD consisted_VBN of_IN patients_NNS with_IN a_DT proven_JJ pneumonia_NN who_WP fulfilled_VBD only_RB one_CD of_IN the_DT criteria_NNS ;_: according_VBG to_TO our_PP$ definition_NN ,_, these_DT patients_NNS were_VBD suffering_VBG from_IN a_DT moderately_RB severe_JJ pneumonia_NN ._SENT CAP_NN category_NN 3_CD consisted_VBN of_IN patients_NNS who_WP presented_VBD with_IN two_CD or_CC more_JJR criteria_NNS ;_: these_DT patients_NNS were_VBD considered_VBN to_TO be_VB suffering_VBG from_IN severe_JJ pneumonia_NN ._SENT Collection_NN of_IN urine_NN samples_NNS ._SENT |_SYM All_DT medical_JJ microbiologists_NNS who_WP had_VBD assisted_VBN in_IN the_DT diagnosis_NN and_CC treatment_NN of_IN the_DT pneumonia_NN patients_NNS in_IN to_TO this_DT outbreak_NN were_VBD asked_VBN to_TO send_VB available_JJ urine_NN samples_NNS from_IN the_DT patients_NNS to_TO the_DT Regional_NP Laboratory_NP of_IN Public_NP Health_NP in_IN Haarlem_NP ,_, The_DT Netherlands_NPS ._SENT After_IN collection_NN ,_, the_DT urine_NN samples_NNS were_VBD stored_VBN in_IN portions_NNS at_IN -70C_NN ._SENT All_DT but_CC eight_CD available_JJ urine_NN samples_NNS had_VBD been_VBN collected_VBN during_IN the_DT hospital_NN stay_NN ._SENT In_IN four_CD cases_NNS ,_, the_DT urine_NN samples_NNS had_VBD been_VBN obtained_VBN shortly_RB before_IN admission_NN ,_, and_CC in_IN four_CD cases_NNS ,_, they_PP had_VBD been_VBN obtained_VBN after_IN discharge_NN from_IN hospital_NN ._SENT Urinary_JJ antigen_NN tests_NNS ._SENT |_SYM The_DT presence_NN of_IN L._NP pneumophila_NP antigens_NNS in_IN urine_NN samples_NNS was_VBD investigated_VBN by_IN using_VBG the_DT Binax_NP (_( Portland_NP ,_, Maine_NP )_) and_CC Biotest_NP (_( Biotest_NP AG_NP ,_, Dreieich_NP ,_, Germany_NP )_) Legionella_NP urinary_JJ antigen_NN tests_NNS ,_, both_CC EIAs_NP ,_, and_CC with_IN the_DT Binax_NP NOW_NP test_NN ,_, a_DT qualitative_JJ ICT_NN ._SENT All_DT tests_NNS were_VBD used_VBN as_IN specified_VBN by_IN the_DT manufacturers_NNS ._SENT However_RB ,_, to_TO ensure_VB maximum_JJ specificity_NN for_IN the_DT ICT_NN ,_, samples_NNS giving_VBG positive_JJ tests_NNS were_VBD reexamined_VBN after_IN 60_CD min_NN ._SENT Urine_NN samples_NNS were_VBD tested_VBN nonconcentrated_JJ and_CC ,_, to_TO enhance_VB the_DT intensity_NN of_IN the_DT reaction_NN ,_, after_IN concentration_NN by_IN selective_JJ ultrafiltration_NN (_( Minicon_NP B15_NP ;_: Millipore_NP Corp._NP Bed_NP Ford_NP ,_, Mass._NP )_) ._SENT This_DT selective_JJ ultrafiltration_NN system_NN consists_VBZ of_IN a_DT permeable_JJ membrane_NN that_WDT permits_VBZ the_DT passage_NN of_IN water_NN and_CC substances_NNS with_IN molecular_JJ weights_NNS less_JJR than_IN 15,000_CD ._SENT Statistics_NNS ._SENT |_SYM Statistical_NP analysis_NN was_VBD performed_VBN with_IN the_DT statistical_JJ program_NN SPSS_NP version_NN 10.0_CD (_( Statistical_NP Product_NP and_CC Service_NP Solutions_NP ,_, Chicago_NP ,_, Ill._NP )_) ._SENT Univariate_JJ analysis_NN (_( chi-square_NN test_NN for_IN dichotomous_JJ and_CC ordinal_JJ variables_NNS ;_: independent_JJ t_NN test_NN for_IN discrete_JJ variables_NNS )_) was_VBD used_VBN to_TO calculate_VB the_DT association_NN with_IN positive_JJ urinary_JJ antigen_NN test_NN results_NNS for_IN the_DT following_VBG variables_NNS :_: age_NN ,_, gender_NN ,_, clinical_JJ severity_NN ,_, number_NN of_IN days_NNS between_IN onset_NN of_IN symptoms_NNS and_CC collection_NN of_IN first_JJ urine_NN sample_NN ,_, and_CC number_NN of_IN times_NNS a_DT urine_NN sample_NN was_VBD collected_VBN ._SENT Variables_NNS that_WDT were_VBD (_( borderline_JJ )_) significant_JJ were_VBD entered_VBN in_IN a_DT multiple_JJ logistic_JJ regression_NN model_NN ._SENT Using_VBG backward_JJ elimination_NN ,_, independent_JJ predictors_NNS for_IN test_NN positivity_NN were_VBD established_VBN ._SENT Variables_NNS were_VBD retained_VBN in_IN the_DT model_NN if_IN the_DT likelihood_NN ratio_NN test_NN was_VBD significant_JJ (_( P_NN <_SYM 0.1_CD )_) ._SENT Patient_JJ selection_NN and_CC classification_NN of_IN disease_NN severity_NN ._SENT |_SYM In_IN the_DT 1999_CD outbreak_NN ,_, 188_CD LD_JJ patients_NNS were_VBD diagnosed_VBN ,_, of_IN whom_WP 133_NP fulfilled_VBD the_DT criteria_NNS for_IN a_DT confirmed_VBN case_NN ._SENT Of_IN the_DT patients_NNS with_IN confirmed_VBN cases_NNS ,_, 132_CD had_VBD been_VBN hospitalized_VBN and_CC were_VBD enrolled_VBN in_IN this_DT study_NN ._SENT A_DT large_JJ number_NN of_IN patients_NNS in_IN this_DT outbreak_NN (_( 51_CD patients_NNS )_) were_VBD diagnosed_VBN by_IN a_DT urinary_JJ antigen_NN test_NN alone_RB ,_, leaving_VBG 81_CD patients_NNS for_IN evaluation_NN ._SENT For_IN 58_CD (_( 72_CD %_NN )_) of_IN these_DT 81_CD patients_NNS ,_, urine_NN samples_NNS were_VBD available_JJ ._SENT The_DT microbiological_JJ diagnosis_NN in_IN these_DT cases_NNS was_VBD established_VBN by_IN culture_NN alone_RB in_IN 11_CD cases_NNS ,_, by_IN culture_NN and_CC serologic_JJ testing_NN in_IN 14_CD cases_NNS ,_, and_CC by_IN serologic_JJ testing_NN alone_RB in_IN 33_CD cases_NNS ._SENT For_IN 55_CD of_IN the_DT 58_CD confirmed_VBN cases_NNS with_IN available_JJ urine_NN samples_NNS ,_, data_NNS on_IN clinical_JJ severity_NN could_MD be_VB collected_VBN ._SENT Women_NNS were_VBD overrepresented_VBN in_IN CAP_NP category_NN 1_CD (_( 67_CD %_NN )_) ,_, in_IN contrast_NN to_TO CAP_NP categories_NNS 2_CD (_( 25_CD %_NN )_) and_CC 3_CD (_( 39_CD %_NN )_) ._SENT The_DT median_JJ age_NN for_IN women_NNS was_VBD lower_JJR then_RB for_IN men_NNS in_IN categories_NNS 1_CD and_CC 2_CD (_( 64_CD and_CC 73_CD years_NNS and_CC 57_CD and_CC 63_CD years_NNS ,_, respectively_RB )_) ,_, in_IN contrast_NN to_TO category_NN 3_CD (_( 70_CD and_CC 62_CD years_NNS ,_, respectively_RB )_) ._SENT Mean_JJ age_NN did_VBD not_RB differ_VB significantly_RB between_IN CAP_NN categories_NNS ,_, but_CC the_DT age_NN difference_NN between_IN male_JJ and_CC female_JJ subgroups_NNS in_IN the_DT lowest_JJS CAP_NN category_NN was_VBD significant_JJ (_( independent_JJ t_NN test_NN ;_: P_NN =_SYM 0.04_CD )_) ._SENT All_DT patients_NNS who_WP were_VBD classified_VBN in_IN CAP_NP category_NN 3_CD needed_VBN medical_JJ attention_NN in_IN a_DT specialized_JJ unit_NN ._SENT Nonconcentrated_JJ urine_NN samples_NNS ._SENT |_SYM Using_VBG nonconcentrated_JJ urine_NN ,_, the_DT sensitivities_NNS calculated_VBN for_IN the_DT three_CD tests_NNS were_VBD 71_CD ,_, 69_CD ,_, and_CC 72_CD %_NN for_IN the_DT Biotest_NP EIA_NP ,_, Binax_NP EIA_NP ,_, and_CC Binax_NP NOW_NP test_NN ,_, respectively_RB ._SENT The_DT differences_NNS between_IN the_DT test_NN sensitivities_NNS were_VBD not_RB significant_JJ ._SENT When_WRB the_DT LD_JJ patients_NNS were_VBD divided_VBN in_IN three_CD groups_NNS according_VBG to_TO their_PP$ CAP_NN category_NN ,_, it_PP appeared_VBD that_IN the_DT average_JJ sensitivities_NNS for_IN the_DT three_CD urinary_JJ antigen_NN tests_NNS increased_VBN from_IN 42_CD %_NN for_IN patients_NNS in_IN the_DT lowest_JJS CAP_NN category_NN to_TO 75_CD %_NN for_IN those_DT in_IN CAP_NP category_NN 2_CD and_CC 93_CD %_NN for_IN those_DT in_IN CAP_NP category_NN 3_CD ._SENT The_DT individual_JJ sensitivities_NNS of_IN the_DT three_CD tests_NNS when_WRB used_VBN with_IN nonconcentrated_JJ urine_NN samples_NNS are_VBP shown_VBN in_IN Fig._NN ._SENT Table_NN shows_VBZ variables_NNS which_WDT in_IN univariate_JJ analysis_NN were_VBD significantly_RB associated_VBN with_IN test_NN positivity_NN ._SENT Age_NN was_VBD not_RB associated_VBN with_IN test_NN positivity_NN ._SENT Multiple_JJ logistic_JJ regression_NN analysis_NN showed_VBD that_IN the_DT CAP_NP category_NN remained_VBD associated_VBN with_IN test_NN positivity_NN in_IN all_DT tests_NNS used_VBD ._SENT Separate_JJ analysis_NN for_IN male_JJ and_CC female_JJ patients_NNS gave_VBD identical_JJ results_NNS ,_, indicating_VBG that_IN the_DT association_NN was_VBD not_RB modified_VBN by_IN gender_NN ._SENT Concentrated_JJ urine_NN samples_NNS ._SENT |_SYM After_IN concentration_NN of_IN the_DT urine_NN samples_NNS for_IN all_DT three_CD tests_NNS ,_, a_DT clear_JJ but_CC not_RB statistically_RB significant_JJ increase_NN in_IN sensitivities_NNS was_VBD found_VBN :_: to_TO 74_CD ,_, 79_CD ,_, and_CC 81_CD %_NN for_IN the_DT Biotest_NP EIA_NP ,_, Binax_NP EIA_NP ,_, and_CC Binax_NP NOW_NP test_NN ,_, respectively_RB ._SENT This_DT increase_NN in_IN sensitivity_NN was_VBD small_JJ in_IN the_DT Biotest_NP EIA_NP (_( 3_CD %_NN )_) and_CC more_RBR prominent_JJ in_IN the_DT Binax_NP EIA_NP (_( 10_CD %_NN )_) and_CC Binax_NP NOW_NP assay_NN (_( 9_CD %_NN )_) ._SENT When_WRB test_NN sensitivity_NN results_NNS were_VBD compared_VBN for_IN categories_NNS with_IN increasing_VBG clinical_JJ severity_NN ,_, concentration_NN of_IN urine_NN samples_NNS yielded_VBD higher_JJR sensitivities_NNS predominantly_RB for_IN patients_NNS in_IN CAP_NP categories_NNS 1_CD and_CC 2_CD ._SENT CAP_NN category_NN ,_, male_JJ gender_NN ,_, number_NN of_IN urine_NN samples_NNS ,_, and_CC shorter_JJR period_NN between_IN onset_NN of_IN symptoms_NNS and_CC collection_NN of_IN the_DT first_JJ urine_NN sample_NN were_VBD associated_VBN with_IN a_DT positive_JJ test_NN result_NN ,_, but_CC age_NN was_VBD not_RB (_( individual_JJ test_NN results_NNS are_VBP given_VBN in_IN Table_NP )_) ._SENT Multiple_JJ logistic_JJ regression_NN analysis_NN showed_VBD that_IN the_DT CAP_NP category_NN was_VBD the_DT only_JJ factor_NN associated_VBN with_IN test_NN positivity_NN in_IN all_DT tests_NNS used_VBN (_( see_VB Table_NP )_) ._SENT Separate_JJ analysis_NN for_IN male_JJ and_CC female_JJ patients_NNS gave_VBD identical_JJ results_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Sensitivity_NN for_IN three_CD urinary_JJ L._NP pneumophila_NN Sensitivity_NN for_IN three_CD urinary_JJ L._NP pneumophila_NN antigen_NN tests_NNS in_IN different_JJ categories_NNS of_IN clinical_JJ severity_NN ,_, using_VBG concentrated_JJ and_CC unconcentrated_JJ urine_NN ._SENT TABLE_NN 1_CD |_SYM Odds_NNS ratios_NNS and_CC mean_VB differences_NNS with_IN confidence_NN interval_NN for_IN variables_NNS associated_VBN with_IN urinary_JJ L._NP pneumophila_NN antigen_NN test_NN positivity_NN TABLE_NP 2_CD |_SYM Multiple_JJ logistic_JJ regression_NN models_NNS showing_VBG odds_NNS ratios_NNS with_IN confidence_NN interval_NN for_IN variables_NNS associated_VBN with_IN urinary_JJ L._NP pneumophila_NN antigen_NN test_NN positivity_NN The_DT first_JJ urinary_JJ antigen_NN tests_NNS ,_, based_VBN on_IN an_DT ELISA_NP ,_, were_VBD described_VBN in_IN 1979_CD ._SENT Since_IN then_RB ,_, numerous_JJ publications_NNS have_VBP followed_VBN that_IN confirmed_VBN the_DT value_NN of_IN urinary_JJ antigen_NN detection_NN for_IN the_DT diagnosis_NN of_IN Legionnaires_NP '_POS disease_NN ,_, regardless_RB of_IN the_DT technical_JJ configuration_NN of_IN the_DT test_NN (_( ,_, ,_, ,_, ,_, -_: )_) ._SENT Based_VBN on_IN prospective_JJ and_CC retrospective_JJ studies_NNS using_VBG data_NNS from_IN solitary_JJ cases_NNS ,_, moderate_JJ to_TO high_JJ urinary_JJ antigen_NN test_NN sensitivities_NNS have_VBP been_VBN described_VBN ._SENT All_DT reported_VBN test_NN sensitivities_NNS are_VBP based_VBN on_IN studies_NNS using_VBG sporadic_JJ LD_JJ cases_NNS ._SENT Most_JJS of_IN these_DT studies_NNS used_VBD a_DT selection_NN of_IN patients_NNS or_CC were_VBD retrospective_JJ ;_: they_PP are_VBP thereby_RB subject_JJ to_TO selection_NN bias_NN ._SENT Some_DT of_IN them_PP include_VBP patients_NNS with_IN LD_NN caused_VBN by_IN other_JJ serogroups_NNS than_IN serogroup_NN 1_CD ,_, which_WDT leads_VBZ to_TO underestimation_NN of_IN the_DT test_NN sensitivity_NN ._SENT Furthermore_RB ,_, the_DT clinical_JJ conditions_NNS of_IN the_DT patients_NNS described_VBN in_IN these_DT studies_NNS were_VBD not_RB taken_VBN into_IN account_NN ,_, which_WDT may_MD explain_VB the_DT range_NN of_IN sensitivity_NN values_NNS found_VBN by_IN different_JJ authors_NNS ._SENT To_TO our_PP$ knowledge_NN ,_, there_EX are_VBP no_DT publications_NNS on_IN test_NN sensitivities_NNS in_IN an_DT outbreak_NN situation_NN ._SENT The_DT 1999_CD outbreak_NN in_IN The_DT Netherlands_NPS provided_VBD a_DT unique_JJ opportunity_NN to_TO evaluate_VB urinary_JJ antigen_NN tests_NNS in_IN an_DT outbreak_NN caused_VBN by_IN an_DT identified_VBN L._NP pneumophila_NP serogroup_NN 1_CD strain_NN ._SENT A_DT nationwide_JJ alert_NN for_IN LD_JJ cases_NNS ensured_VBD optimal_JJ case_NN finding_NN ,_, thereby_RB decreasing_VBG patient_JJ selection_NN bias_NN ._SENT Furthermore_RB ,_, the_DT conditions_NNS for_IN a_DT gold_JJ standard_NN were_VBD favorable_JJ :_: two_CD national_JJ reference_NN laboratories_NNS performed_VBD all_DT microbiological_JJ tests_NNS ,_, and_CC Dutch_JJ reference_NN titers_NNS were_VBD calculated_VBN using_VBG the_DT distribution_NN of_IN antibodies_NNS against_IN L._NP pneumophila_NP serogroup_NN 1_CD in_IN a_DT large_JJ sample_NN from_IN a_DT national_JJ serum_NN bank_NN ._SENT In_IN addition_NN ,_, all_DT available_JJ clinical_JJ data_NNS for_IN the_DT LD_JJ patients_NNS in_IN this_DT outbreak_NN were_VBD recorded_VBN centrally_RB ._SENT Assuming_VBG that_DT patient_JJ inclusion_NN in_IN an_DT outbreak_NN situation_NN resembles_VBZ a_DT prospective_JJ study_NN design_NN ,_, our_PP$ data_NNS are_VBP best_RBS compared_VBN with_IN the_DT published_VBN results_NNS of_IN two_CD prospective_JJ studies_NNS on_IN urinary_JJ antigen_NN test_NN sensitivity_NN in_IN LD_NP ._SENT One_CD study_NN included_VBD a_DT single_JJ high_JJ titer_NN in_IN the_DT gold_JJ standard_NN ,_, inherently_RB lowering_VBG the_DT test_NN sensitivity_NN to_TO be_VB measured_VBN on_IN the_DT basis_NN of_IN misclassification_NN ._SENT In_IN this_DT study_NN ,_, however_RB ,_, a_DT higher_JJR sensitivity_NN (_( 84_CD %_NN )_) was_VBD found_VBN for_IN patients_NNS with_IN LD_NN caused_VBN by_IN L._NP pneumophila_NP serogroup_NN 1_CD ._SENT The_DT other_JJ prospective_JJ study_NN included_VBD patients_NNS with_IN LD_NN caused_VBN by_IN L._NP pneumophila_NP serogroups_NNS 1_CD ,_, 3_CD ,_, and_CC 7_CD ,_, making_VBG a_DT lower_JJR sensitivity_NN more_RBR likely_JJ on_IN the_DT basis_NN of_IN a_DT low_JJ urine_NN antigen_NN detection_NN capacity_NN for_IN other_JJ serogroups_NNS than_IN serogroup_NP 1_CD ._SENT Indeed_RB ,_, the_DT reported_VBN sensitivity_NN in_IN this_DT study_NN was_VBD lower_JJR (_( 57_CD %_NN )_) ._SENT Since_IN the_DT 1999_CD outbreak_NN in_IN The_DT Netherlands_NPS was_VBD caused_VBN by_IN an_DT L._NP pneumophila_NN strain_NN of_IN serogroup_NN 1_CD ,_, high_JJ sensitivities_NNS for_IN the_DT three_CD tests_NNS were_VBD to_TO be_VB expected_VBN ._SENT However_RB ,_, overall_JJ test_NN sensitivities_NNS found_VBN in_IN this_DT study_NN were_VBD lower_JJR than_IN those_DT reported_VBN by_IN Ruf_NP et_FW al._FW and_CC ranged_VBD from_IN 69_CD to_TO 72_CD %_NN for_IN nonconcentrated_JJ urine_NN samples_NNS ._SENT This_DT lower_JJR sensitivity_NN may_MD be_VB explained_VBN by_IN a_DT difference_NN in_IN the_DT study_NN populations_NNS ._SENT Active_JJ case_NN finding_VBG for_IN LD_NN in_IN this_DT outbreak_NN may_MD have_VB resulted_VBN in_IN hospitalization_NN of_IN a_DT higher_JJR proportion_NN of_IN patients_NNS with_IN relatively_RB mild_JJ LD_NN compared_VBN to_TO a_DT nonoutbreak_NN situation_NN ._SENT As_IN our_PP$ results_NNS show_VBP ,_, the_DT sensitivity_NN of_IN urinary_JJ antigen_NN tests_NNS is_VBZ relatively_RB low_JJ for_IN cases_NNS in_IN CAP_NP categories_NNS 1_CD and_CC 2_CD ._SENT We_PP do_VBP not_RB know_VB of_IN a_DT published_VBN study_NN in_IN which_WDT an_DT association_NN between_IN the_DT severity_NN of_IN disease_NN and_CC the_DT test_NN sensitivity_NN for_IN LD_NP has_VBZ been_VBN demonstrated_VBN ,_, although_IN one_CD study_NN hinted_VBN at_IN such_PDT an_DT association_NN ._SENT The_DT association_NN between_IN sensitivity_NN and_CC clinical_JJ severity_NN demonstrated_VBN in_IN the_DT present_JJ study_NN has_VBZ clinical_JJ and_CC diagnostic_JJ consequences_NNS ._SENT Because_IN of_IN the_DT high_JJ sensitivity_NN in_IN patients_NNS with_IN a_DT severe_JJ pneumonia_NN ,_, the_DT early_JJ recognition_NN of_IN patients_NNS with_IN life-threatening_JJ LD_NN can_MD prevent_VB delay_NN in_IN initiating_VBG adequate_JJ antibiotic_JJ therapy_NN ._SENT However_RB ,_, the_DT urinary_JJ antigen_NN test_NN is_VBZ less_RBR reliable_JJ in_IN milder_JJR cases_NNS of_IN LD_NP ,_, indicating_VBG that_IN this_DT diagnostic_JJ test_NN ,_, despite_IN its_PP$ rapid_JJ interpretation_NN ,_, cannot_MD replace_VB culture_NN and_CC serologic_JJ testing_NN ._SENT Therefore_RB ,_, in_IN the_DT setting_NN of_IN persistent_JJ clinical_JJ or_CC epidemiological_JJ suspicion_NN of_IN LD_NP and_CC a_DT negative_JJ urinary_JJ antigen_NN test_NN result_NN in_IN patients_NNS in_IN whom_WP no_DT other_JJ microorganism_NN is_VBZ identified_VBN ,_, culture_NN and_CC serologic_JJ testing_NN are_VBP recommended_VBN and_CC treatment_NN must_MD include_VB antibiotic_JJ coverage_NN for_IN Legionella_NP ._SENT When_WRB the_DT detection_NN of_IN antigens_NNS in_IN urine_NN during_IN an_DT outbreak_NN is_VBZ used_VBN for_IN epidemiological_JJ purposes_NNS ,_, one_PP has_VBZ to_TO keep_VB in_IN mind_NN that_IN 50_CD to_TO 60_CD %_NN of_IN cases_NNS of_IN mild_JJ pneumonia_NN will_MD stay_VB undiscovered_JJ ,_, depending_VBG on_IN whether_IN urine_NN is_VBZ concentrated_JJ (_( concentration_NN improves_VBZ the_DT chance_NN of_IN detection_NN )_) ._SENT This_DT implies_VBZ that_IN ,_, due_JJ to_TO undiagnosed_JJ cases_NNS ,_, the_DT size_NN of_IN an_DT outbreak_NN will_MD be_VB underestimated_VBN unless_IN complementary_JJ diagnostic_JJ serologic_JJ tests_NNS using_VBG paired_VBN sera_NN are_VBP performed_VBN in_IN all_DT suspected_JJ cases_NNS ._SENT Because_IN seroconversion_NN can_MD take_VB up_RP to_TO 9_CD weeks_NNS after_IN onset_NN of_IN the_DT disease_NN ,_, a_DT prolonged_JJ interval_NN between_IN collection_NN of_IN the_DT two_CD sera_NN is_VBZ advisable_JJ for_IN reliable_JJ interpretation_NN of_IN serologic_JJ results_NNS ._SENT Like_IN other_JJ researchers_NNS ,_, we_PP were_VBD unable_JJ to_TO demonstrate_VB a_DT significant_JJ difference_NN in_IN sensitivity_NN between_IN the_DT two_CD EIAs_NNS that_WDT were_VBD tested_VBN and_CC the_DT ICT_NN ._SENT Since_IN the_DT latter_NN is_VBZ very_RB easy_JJ to_TO perform_VB without_IN special_JJ laboratory_NN equipment_NN and_CC the_DT results_NNS are_VBP available_JJ at_IN short_JJ notice_NN even_RB after_IN concentration_NN of_IN the_DT urine_NN samples_NNS ,_, this_DT test_NN may_MD be_VB preferable_JJ in_IN outbreak_NN situations_NNS if_IN serogroup_NN 1_CD is_VBZ involved_VBN ._SENT Previous_JJ studies_NNS have_VBP also_RB demonstrated_VBN that_IN a_DT higher_JJR sensitivity_NN of_IN urinary_JJ antigen_NN detection_NN was_VBD found_VBN using_VBG concentrated_JJ urine_NN ,_, regardless_RB of_IN the_DT test_NN used_VBD ._SENT Concentration_NN by_IN ultrafiltration_NN is_VBZ easy_JJ to_TO perform_VB and_CC can_MD facilitate_VB an_DT early_JJ diagnosis_NN ,_, especially_RB in_IN milder_JJR cases_NNS ._SENT In_IN conclusion_NN ,_, in_IN outbreak_NN situations_NNS the_DT urinary_JJ antigen_NN tests_NNS are_VBP a_DT useful_JJ tool_NN for_IN early_JJ diagnosis_NN of_IN LD_NP ,_, especially_RB in_IN patients_NNS with_IN severe_JJ cases_NNS ._SENT The_DT ICT_NN scored_VBD at_IN least_JJS equal_JJ to_TO the_DT EIAs_NNS and_CC has_VBZ the_DT advantage_NN of_IN ease_NN of_IN performance_NN combined_VBN with_IN rapid_JJ test_NN results_NNS ._SENT Concentration_NN of_IN the_DT urine_NN samples_NNS increases_VBZ the_DT sensitivity_NN ,_, particularly_RB in_IN patients_NNS with_IN less_JJR severe_JJ illness_NN ,_, and_CC is_VBZ therefore_RB recommended_VBN ._SENT In_IN outbreak_NN situations_NNS ,_, the_DT use_NN of_IN urinary_JJ antigen_NN tests_NNS alone_RB for_IN evaluation_NN of_IN the_DT incidence_NN rate_NN will_MD lead_VB to_TO underestimation_NN of_IN the_DT actual_JJ incidence_NN ._SENT Therefore_RB ,_, culture_NN and_CC serologic_JJ testing_NN remain_VBP necessary_JJ diagnostic_JJ tools_NNS ._SENT TABLE_NN 3_CD |_SYM Overview_NN of_IN urinary_JJ antigen_NN test_NN sensitivity_NN for_IN sporadic_JJ cases_NNS of_IN LD_NP 